{"id":"W2977457247","doi":"10.1093/annonc/mdz249.018","title":"Three-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Docetaxel; Pembrolizumab; Urothelial cancer; Oncology; Paclitaxel; Internal medicine; Chemotherapy; Cancer; Bladder cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007011215,0.001386527,0.00479037,0.0006132761,0.001663151,0.002344498,0.001063415,0.002963707,0.006356817],"category_scores_gemma":[0.005284965,0.0005789583,0.004911492,0.0008454254,0.0008157557,0.002574054,0.001139651,0.006003462,0.00152154],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001427653,"about_ca_system_score_gemma":0.001312145,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004507164,"about_ca_topic_score_gemma":0.005712834,"domain_scores_codex":[0.9980189,0.0006252935,0.0001528307,0.0003929938,0.0002383626,0.0005715286],"domain_scores_gemma":[0.9955525,0.0009628271,0.0008413084,0.0005803196,0.0005353907,0.001527708],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8668499,0.008672219,0.03224326,0.0006859743,0.007902352,0.0005121774,0.0003047389,0.004501036,0.00448764,0.0002961239,0.01516538,0.05837923],"study_design_scores_gemma":[0.2319562,0.2381549,0.4746077,0.0003596402,0.01943288,0.001123572,0.0005716272,0.003761093,0.00436541,0.002043221,0.0233327,0.0002911463],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9493681,0.01189517,0.001837452,0.002383875,0.0008032933,0.001248977,0.02432132,0.0001810977,0.00796065],"genre_scores_gemma":[0.9539716,0.001739985,0.0006099454,0.003225192,0.0003184997,0.0007279812,0.03303308,0.00007933349,0.006294347],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007011215,"threshold_uncertainty_score":0.03707933,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1329164650537229,"score_gpt":0.4271093793534019,"score_spread":0.294192914299679,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}